Prevalensi resus negatif sejak 2021: A systematic literature review
DOI: https://doi.org/10.33024/hjk.v19i11.1681
Golongan Darah ABO Hemolytic Disease Of The Fetus And Newborn (HDFN) Prevalensi Resus Negatif RhD-
Abstract
Background: Rhesus negativity (rhd−) is a hematological phenotype with important clinical implications, particularly in pregnancy and blood transfusion. Isoimmunization due to rhesus incompatibility can lead to hemolytic disease of the fetus and newborn (HDFN).
Purpose: To identify and analyze the global prevalence of rhesus negativity.
Method: A systematic literature review was conducted using the keywords "rhd-negative prevalence worldwide 2020–2025" and screened for peer-reviewed articles published in English since 2020. Data selection and extraction were performed by analyzing study quality using tools such as the Newcastle-Ottawa Scale (NOS), screening titles, abstracts, and full texts, and extracting key variables: location, sample size, detection method, and prevalence outcomes.
Results: A systematic literature review (SLR) from 2020 to 2025 revealed an average rhesus-negative prevalence of 8% in populations from Nigeria, Ethiopia, Libya, India, Bangladesh, and Saudi Arabia, with blood type B (27%) being the most common. Genetic factors, ethnicity, migration, and marriage practices influence this variation, further amplified by sociodemographic factors such as health care access and urbanization. Clinical implications include the importance of Rh screening and anti-D prophylaxis to prevent isoimmunization and obstetric complications, particularly in developing countries.
Conclusion: The average rhd- prevalence in the global population was found to be 8%, with blood type B (27%) being the most common. These findings emphasize the urgency of harmonizing research methodologies and strengthening evidence-based maternal and newborn health policies. Global collaboration is essential to improve understanding and response to rhd- risks, particularly in resource-limited countries.
Keywords: ABO Blood Group; Hemolytic Disease of the Fetus and Newborn (HDFN); Prevalence of Rhesus negative; RhD-.
Pendahuluan: Rhesus negatif (rhd−) adalah fenotipe hematologis yang memiliki implikasi klinis penting, khususnya dalam kehamilan dan transfusi darah. Isoimunisasi akibat ketidakcocokan rhesus dapat menyebabkan penyakit hemolitik janin dan bayi baru lahir atau hemolytic disease of the fetus and newborn (HDFN).
Tujuan: Untuk mengidentifikasi dan menganalisis prevalensi rhesus negatif secara global.
Metode: Penelitian systematic literature review dari database Google Scholar, Scopus, dan Pubmed menggunakan kata kunci “prevalence rhesus negatifity worldwide 2020–2025” dan menggunakan filter artikel peer-reviewed, bahasa Inggris, publikasi sejak 2020. Proses seleksi dan ektrasi data dilakukan dengan cara menganalisis kualitas studi dengan alat seperti Newcastle-Ottawa Scale (NOS), melakukan proses screening judul, abstrak, dan full text serta ekstraksi variabel utama yaitu lokasi, ukuran sampel, metode deteksi, dan hasil prevalensi.
Hasil: Temuan sistematik literatur review (SLR) selama 202-2025, mengungkap prevalensi rhesus negatif rerata sebesar 8% pada populasi dari Nigeria, Ethiopia, Libya, India, Bangladesh, dan Arab Saudi, dengan distribusi golongan darah terbanyak pada tipe B (27%). Faktor genetik, etnis, migrasi, dan praktik pernikahan memengaruhi keragaman ini, serta diperkuat oleh faktor sosiodemografi seperti akses kesehatan dan urbanisasi. Implikasi klinis meliputi pentingnya skrining Rh dan profilaksis anti-D untuk mencegah isoimunisasi dan komplikasi obstetri, khususnya di negara berkembang.
Simpulan: Rerata prevalensi rhd− pada populasi global ditemukan sebesar 8%, dengan distribusi terbanyak pada golongan darah B (27%). Temuan ini menekankan urgensi harmonisasi metodologi penelitian dan penguatan kebijakan kesehatan maternal-neonatal berbasis bukti. Kolaborasi global sangat diperlukan untuk meningkatkan pemahaman dan respons terhadap risiko rhd−, terutama di negara dengan sumber daya terbatas.
Kata Kunci: Golongan Darah ABO; Hemolytic Disease Of The Fetus And Newborn (HDFN); Prevalensi Resus Negatif; RhD-.
Downloads
References
Adeyemi, A., & Bello-Ajao, H. (2016). Prevalence of Rhesus D-negative blood type and the challenges of Rhesus D immunoprophylaxis among obstetric population in Ogbomoso, Southwestern Nigeria. Annals of Tropical Medicine and Public Health, 9(1), 12-12.
Aliyo, A., Ashenafi, G., & Abduselam, M. (2023). Rhesus negativity prevalence and neonatal outcomes among pregnant women delivered at Bule Hora University teaching hospital, west Guji zone, south Ethiopia. Clinical Medicine Insights: Pediatrics, 17, 11795565221145598.
Arora, D., Dey, M., Kumar, A., & Nair, V. G. (2022). Management of Rh-negative Alloimmunized Pregnancy Optimizing Perinatal Mortality and Morbidity: A Single-center Study. International Journal of Infertility & Fetal Medicine, 13(3), 111-115.
Babu, K. S., Praveen, M. D., & Babu, B. S. (2024). Phenotypic Frequency of Clinically Significant Blood Group Antigens (Rh, Kell, Kidd, and Duffy) in Blood Donors of the Blood Center at a Tertiary Care Referral Teaching Hospital in Tirupati, Andhra Pradesh, South India. Global Journal of Transfusion Medicine, 9(1), 45-50.
Bassey, E. A., Abah, M. G., Opone, C. A., & Jackson, A. L. (2021). Prevalence of Rhesus Negative Status Amongst Antenatal Atendees in the University of Uyo Teaching Hospital, Uyo, Nigeria: A 5-Year Review. World Health, 11(13), 14.
Bidayah, H. F., Pratiwi, R., & Triyono, T. (2025). Dinamika Golongan Darah Sistem ABO: Pendekatan Seluler hingga Molekuler. UGM PRESS.
Butler, E. A., Parikh, R., Grandi, S. M., Ray, J. G., & Cohen, E. (2023). ABO and Rh blood groups and risk of infection: systematic review and meta-analysis. BMC Infectious Diseases, 23(1), 797.
Cifuentes, M. Z. C., Pastore, Y. D., Nguyen, T. D., Bérubé, D., & Dahdah, N. (2021). 141 Sickle cell disease and physical activity: Is it safe?. Paediatrics & Child Health, 26(Suppl 1), e98.
Cordell, V., Soe, A., Latham, T., Bills, V. L., & Royal College of Obstetricians and Gynaecologists. (2025). The Use of Novel Therapies in the Management of Haemolytic Disease of the Fetus and Newborn (HDFN) Scientific Impact Paper No. 75. BJOG: An International Journal of Obstetrics & Gynaecology, 132(4), e53-e60.
Daniels, G. (2023). An overview of blood group genotyping. Annals of Blood, 8.
Dziegiel, M. H., Krog, G. R., Hansen, A. T., Olsen, M., Lausen, B., Nørgaard, L. N., & Clausen, F. B. (2021). Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn. Transfusion Medicine and Hemotherapy, 48(5), 306-315.
Ejiroghene, E., Oboratare, O., & Oghenero, O. P. (2025). Prevalence of Rhesus-D negativity among antenatal attendees in Central Hospital Warri, Delta State, Nigeria. Dutse Journal of Pure and Applied Sciences, 11(1d), 183-189.
Gemzell‐Danielsson, K., Cameron, S., Bombas, T., Parachini, M., Lubusky, M., Agostini, A., & Fiala, C. (2025). Rhesus testing and anti‐D prophylaxis in RhD‐negative women undergoing first‐trimester abortion—Systematic Review and Opinion. International Journal of Gynecology & Obstetrics.
Gonnade, N., Bajpayee, A., Elhence, A., Lokhande, V., Mehta, N., & Mishra, M. (2017). and using cord blood for transfusion Azikiwe University Teaching Hospital. vol, 12, 105-111.
Irinmwinuwa, E. O., Mbah, C. A., Oyate, G. B., Festa, O., & John-Iganga, A. (2023). Effect of Rhesus factor incompatibility on maternal outcome (fertility): A comprehensive review. International Journal of Frontiers in Life Science Research, 5(2), 1-7.
Juhl, D., Braun, F., Brockmann, C., Musiolik, I., Bunge‐Philipowski, T., Luckner, K., & Ziemann, M. (2025). Sel darah merah RhD‐negatif dapat diselamatkan selama transplantasi hati pada pasien RhD‐negatif karena risiko aloimunisasi terhadap RhD yang rendah. Transfusion , 65 (1), 50-57.
Kanko, T. K., & Woldemariam, M. K. (2021). Prevalence of Rhesus D negativity among reproductive age women in Southern Ethiopia: a cross-sectional study. BMC Women's Health, 21(1), 161.
Khair, H., Muhallab, S., Al Nuaimi, M., Hilary, S., Al Awar, S., Zaręba, KT, & Ahmed, LA (2024). Profilaksis anti-D antenatal dan negatifnya antigen D pada wanita hamil di UEA: analisis potong lintang dari Studi Mutaba'ah. BMJ open ,
Kwok, K. H., Gissler, M., Thunbo, M. Ø., Hsia, E. C., Tjoa, M. L., Liu, S., & Wikman, A. (2025). Clinical characteristics and outcomes of pregnancies at-risk of hemolytic disease of the fetus and newborn in Sweden, Finland, and Denmark: a population-based register study. AJOG global reports, 5(3), 100544.
Lendabo, F., Srinivasan, V., & Rather, R. A. (2024). Prevalence of ABO and Rhesus (D) Blood Group and Allelic Frequency at Blood Bank of Nigist Eleni Mohammed Hospital, Ethiopia. BioMed Research International, 2024(1), 5353528.
Li, H. Y., & Guo, K. (2022). Blood group testing. Frontiers in medicine, 9, 827619.
Maruta, M. B., Tesfaye, K., Birhanu, E., Yigazu, N., Yuya, M., Debella, A., & Mussa, I. (2023). Prevalence and determinants of RH alloimmunization in Rh-negative women in teaching hospitals of Addis Ababa, Ethiopia: a hospital-based cross-sectional study. Frontiers in Global Women's Health, 4, 1167736.
Moise Jr, K. J., Ling, L. E., Oepkes, D., Tiblad, E., Verweij, E. J., Lopriore, E., & Bussel, J. B. (2024). Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. New England Journal of Medicine, 391(6), 526-537.
Moise Jr, K. J., & Abels, E. A. (2022). Management of red cell alloimmunization in pregnancy. Obstetrics & Gynecology, 10-1097.
Muddathir, A. R. M., Abdallah, E. I., Elradi, W. E. O., Elbasheir, M. E., Abdelgadir, R. E., & Waggiallah, H. A. (2022). Prevalence of HDNF due to ABO, Rh (D) and other blood groups among newborns, Sudan. Journal of Biochemical Technology, 13(1-2022), 25-28.
Nahendran, P., Budin, S. B., Saat, N. Z. M., Yusop, M. F., Yazid, T. N. T., & Anuar, N. N. M. (2023). Haemolytic of newborn disease-related red blood cell alloantibodies. Jurnal Teknologi (Sciences & Engineering), 85(1), 1-9.
Nurul'Adani, S., Ashari, N. S. M., Johan, M. F., Edinur, H. A., Noor, N. H. M., & Hassan, M. N. (2024). Red blood cell alloimmunization in pregnancy: a review of the pathophysiology, prevalence, and risk factors. Cureus, 16(5).
Osmana, Y., & Alkhaldia, M. (2024). Study of Haemolytic Disease of the Foetus and Newborn with Positive Direct Coomb’s Test in Single Centre. Revista Romana de Hematologie, 2(4).
Papageorgiou, N., Sohrabi, C., Bakogiannis, C., Tsarouchas, A., Kukendrarajah, K., Matiti, L., & Providencia, R. (2024). Blood groups and Rhesus status as potential predictors of outcomes in patients with cardiac resynchronisation therapy. Scientific Reports, 14(1), 8371.
Pegoraro, V., Urbinati, D., Visser, G. H., Di Renzo, G. C., Zipursky, A., Stotler, B. A., & Spitalnik, S. L. (2020). Hemolytic disease of the fetus and newborn due to Rh (D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PloS one, 15(7), e0235807.
Pell, L. G., Ariff, S., Khan, G. N., Dampf, H., Jokhio, S. M., Zipursky, A., & Morris, S. K. (2025). Point-of-care determination of the frequency of Rhesus (D)-negative blood types and the uptake of anti (D) immunoglobulin among Rh (D)-negative women in Dadu district, Sindh, Pakistan. PLOS Global Public Health, 5(4), e0004395.
Poetranto, A. L., Idrus, H. H., & Nurwidyaningtyas, W. (2024). Association Between Rhesus and ABO Blood Group Types and Their Impact on Clinical Outcomes in Critically Ill Patients with COVID-19: A Multi-Center Investigation. Infection and Drug Resistance, 3657-3658.
Rahimi‐Levene, N., Chezar, J., Yahalom, V., & Israeli HDFN Study Group Investigators. (2020). Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: a retrospective study. Transfusion, 60(11), 2684-2690.
Slootweg, Y. M., Zwiers, C., Koelewijn, J. M., van der Schoot, E., Oepkes, D., van Kamp, I. L., & de Haas, M. (2022). Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study. BJOG: An International Journal of Obstetrics & Gynaecology, 129(10), 1721-1730.
Tang, T. H., Guo, C. Y., Li, X. Y., Hu, Y. X., Liu, W. K., & Yu, M. X. (2024). Effect of Anti-D titers in RhD-negative pregnant women on fetuses and newborns: A retrospective study. Pediatrics & Neonatology, 65(3), 288-292.
Tariq, F., Ashfaq, J., Ahmed, R., Fatima, N., Ahmed, Y., & Borhany, M. (2022). The frequency of Rh phenotype and its probable genotype. Cureus, 14(6).
Visser, G. H., Thommesen, T., Di Renzo, G. C., Nassar, A. H., Spitalnik, S. L., FIGO Committee for Safe Motherhood, Newborn Health, & Wright, A. (2021). FIGO/ICM guidelines for preventing Rhesus disease: A call to action. International Journal of Gynecology & Obstetrics, 152(2), 144-147.
Wannoon, S., Saringkanan, P., Boonhok, R., Kooltheat, N., & Charong, N. (2024). Preoperative Autologous Blood Donation for Rh-Negative Pregnant Women Undergoing Cesarean Sections. Journal of Clinical Medicine Research, 16(7-8), 335.
Yu, D., Ling, L. E., Krumme, A. A., Tjoa, M. L., & Moise Jr, K. J. (2023). Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010. AJOG Global Reports, 3(2), 100203.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Holistik Jurnal Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
